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Background/aim: Epidermal growth factor receptor (EGFR) family members and their associated ligands may be related to bone and
joint destruction in rheumatoid arthritis. Matrix metalloproteinases are responsible for joint and bone tissue degradation. This study is
intended to investigate the effect of epidermal growth factor receptor inhibition by lapatinib on the synthesis of matrix metalloproteinases
in in vitro.
Materials and methods: Synovial fibroblast cell culture was obtained from a patient with rheumatoid arthritis who underwent knee
arthroplasty. Interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) were added to the cell culture to stimulate synovial fibroblast
cells and create an inflammatory character. Understimulated and nonstimulated conditions, lapatinib was applied to the culture in four
different concentrations of 25, 50, 100, and 200 µmol. Then, matrix metalloproteinase -1, -3, and, -13 levels were assessed.
Results: When stimulated with IL-1β and TNF-α, the synthesis of matrix metalloproteinases from synovial fibroblast was increased
significantly. When lapatinib is added to the stimulated synovial fibroblasts, matrix metalloproteinases synthesis is significantly
suppressed.
Conclusion: Inhibition of the EGFR pathway with lapatinib suppresses matrix metalloproteinases synthesis. Our results suggest EGFR
pathway inhibition may be a promising option to prevent joint destruction in the treatment of rheumatoid arthritis.
Key words: Epidermal growth factor, lapatinib, matrix metalloproteinase, rheumatoid arthritis, synovial fibroblast

1. Introduction
Rheumatoid arthritis (RA) is a disease of unknown
etiopathogenesis characterized by chronic synovial
inflammation, bone erosions, cartilage destruction, and
pannus formation. Angiogenesis and synovial hyperplasia
have an important role in the pathogenesis of the
deformities that develop in RA [1–4].
Angiogenesis, one of the earliest lesions of RA, leads
to hyperplastic synovium, causing progressive destruction
in tendons, joint cartilage, and bone [2–4]. Rheumatoid
synovium, proinflammatory mediators, cathepsin, and
inflammatory cells secreting matrix metalloproteinases
(MMP) play a role in this destruction, and key effector
cells are synovial fibroblasts [4,5]. Epidermal growth
factor (EGF) contributes to the formation of this
proinflammatory and destructive setting in the joint [6].

EGF receptors are essential in the growth of hyperplastic
tumors and angiogenesis. Similarly, these receptors and
their ligands may be associated with synovial hyperplasia,
angiogenesis, and disease progression in RA. RA
synovium is also hyperplastic and invasive, and synovial
fibroblasts commonly express EGF receptors (EGFRs)
and their ligands [3]. Moreover, the increased serum and
joint EGF and EGFR in patients with RA compared with
those in the healthy population have been demonstrated
by several studies [7–10]. Recently, another study
provided the first evidence that EGFR polymorphisms are
associated with the risk of RA development, suggesting
that genetic polymorphisms in EGFR may contribute to
the development of RA [11].
EGFR blockade directly leads to significant
antiangiogenic effects and indirectly suppresses the
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synthesis of other factors with strong angiogenic effects
[12–13]. In addition, EGF has been shown to stimulate the
synthesis of matrix metalloproteinase, which is known to
play an important role in joint destruction [7].
This data suggests that EGFR inhibition may prevent
joint destruction in RA. Lapatinib, a tyrosine kinase
inhibitor, is a reversible inhibitor of orally used EGFR and
human EGFR-2-related tyrosine kinases [6]. This study
aimed to investigate in vitro the effect of lapatinib in the
synthesis of MMP from synovial fibroblast, which is key
effector cells, mediating persistent inflammation, and
destruction of joints.
2. Materials and methods
In this study, the effect of lapatinib, an EGFR tyrosine kinase
inhibitor, was investigated in vitro. Synovial fibroblasts are
planned to be isolated by taking cartilage tissue from a
patient diagnosed with RA (The patient with a seropositive
RA diagnosis for 15 years, had not received DMARD
treatment before except for methotrexate, the methotrexate
treatment was discontinued 1 month before the operation,
there was no comorbidity). Isolated synovial fibroblasts
were inoculated on the appropriate cell culture flask. For
synovial fibroblasts to take gain an inflammatory character,
it was planned to add TNF-α and IL-1β. To test the effect of
lapatinib, synovial fibroblasts were seeded in 10 different
cell culture flasks; Flask 1; Control Flask (not induced
with TNF-α and IL-1β, not treated with lapatinib), Flask
2; Inflammation Flask (induced with TNF-α and IL-1β,

Figure 1. Study design.
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but not treated with lapatinib), Flask 3., 5., 7., and 9.; (not
induced with TNF-α and IL-1β, but treated with lapatinib
25, 50, 100, and 200 µg/L doses), Flask 4., 6., 8., 10; after
stimulation with TNF-α and IL-1β, 25, 50, 100, and 200
µg/l doses of lapatinib were added (Figure 1).
2.1. Biopsy collection and human synovial fibroblasts
isolation and culture
The synovial tissue specimen was taken from a RA patient
in remission at the age of 55, who underwent surgical
joint replacement, and did not take immunosuppressive
medication for 15 days. The RA patient fulfilled the
American College of Rheumatology (ACR)/the European
League Against Rheumatism (EULAR) 2010 classification
criteria for RA.
The cartilage tissues were collected in phosphate buffer
salt (PBS) with antibiotics and kept at 4 °C. The cartilage
slices were minced and digested with 1% trypsin for
0.5 h at 37 °C and subsequently with 0.25% collagenase
overnight in serum-free medium at 37 °C. After digestion,
the suspension containing isolated synovial fibroblasts was
centrifuged (1000 × g for 10 min). The resulting pellet was
washed twice with Dulbecco’s modified eagles medium
(DMEM) to remove the remaining digestive enzyme.
Then, cells were resuspended and cultured in DMEM with
10% fetal bovine serum (FBS) and 1% antibiotic (Lonza,
Switzerland). Within 2–3 days of harvesting, primary
synovial fibroblasts were cultured to 80% confluence and
plated in 24 well and 96-well plates [14].
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2.2. In vitro inflammation study and lapatinib application
in primary synovial fibroblasts culture
In this study, synovial fibroblasts were preexposed to
proinflammatory cytokines such as IL-1β and TNF-α and
initiated inflammation in synovial fibroblasts. Primary
synovial fibroblasts cultures were incubated with serumstarved medium (0.5% FBS). Serum-starved human
articular synovial fibroblasts were prestimulated with
5ng/ml IL-1β and 10 ng/ml TNF-α for 24 h before being
treated with lapatinib (Glaxosmithkline San. ve Tic. AŞ,
İstanbul, Turkey). After overnight, various concentrations
(25, 50, 100, and 200 μM) of lapatinib were administered
to inflammatory cells and incubated for 24 h [15].
2.3. ELISA tests
To investigate the effect of lapatinib on inflammatory cells,
the levels of MMP-1, -3, and, -13 in the culture supernatant
were measured using commercially available enzymelinked immunosorbent assay (ELISA) kits. The samples
were performed six times (n = 6).
2.4. MTS assay
For the cell proliferation assay, synovial fibroblasts were
seeded in triplicate in 96 well plates for 24 h, and then cells
were treated with 5 ng/mL IL-1β and 10 ng/mL TNF-α for
24 h. Then, various concentrations (25, 50, 100, and 200
μM) of lapatinib were administered to inflammatory cells
and incubated.
2.5. Statistical analysis
Based on a previous study [16], the sample size of this
study was eight per group and it was calculated based
on an alpha error of 0.05 and a power of 80% and 90%
(GPower3.1). Data were presented as median (min-max).
Kruskal Wallis one-way analysis of variance was used for
comparisons among the groups (percent viability, MMP-

1, MMP-3, MMP-13), and the Mann-Whitney U test was
used for dual comparisons (percent viability, MMP-1,
MMP-3, MMP-13). Statistical evaluations were performed
using the Statistical Package for the Social Sciences (SPSS)
package program, version 14.0. A P value of < 0.05 was
considered to be significant.
3. Results
To test the effect of EGFR blockade, 10 groups were created;
Group 1 was the Control group, Group 2 was stimulated
with TNF-α and IL-1β, Group 3 was added only lapatinib
at doses of 25, 50, 100, 200 µg/L, and Group 4 was added
lapatinib at doses of 25, 50, 100, 200 µg/L, after stimulating
with TNF-α and IL-1β.
3.1. The productions of MMPs from synovial fibroblasts
The applications of IL-1β and TNF-α on synovial fibroblast
culture increased the production of MMP-1,-3, and-13.
On the other hand, lapatinib suppressed the productions
of MMP-1,-3, and-13 from synovial fibroblasts induced by
IL-1β and TNF-α (Table) (Figure 2A, 2B, 2C).
3.2. The proliferation of synovial fibroblasts
Synovial fibroblasts were isolated from the joint tissue
obtained from the RA patient and stimulated with IL1β and TNF-α to gain inflammatory character. The
applications of IL-1β and TNF-α on synovial fibroblast
cultures proliferated synovial fibroblasts (Figure 3). On
the other hand, lapatinib suppressed the proliferation of
synovial fibroblasts (Table) (Figure 2A, 2B, 2C).
4. Discussion
In this study, it was aimed to investigate the effectiveness of
lapatinib, an EGFR tyrosine kinase inhibitor, on synovial
fibroblasts. For this purpose, synovial fibroblast cell culture

Table. Matrix metalloproteinase -1, -3, and, -13 levels in the study groups.
MMP-1 (pg/mL)

MMP-3 (pg/mL)

MMP-13 (pg/m)

Control group

1680 (1490–1870)a

1199 (891–1348)a

55.2 (49.0–60.3)a

The group induced by TNF-α and IL-1β

3440 (3245–3745)

3111 (2218–4268)

88.6 (74.2–94.2)

Lapatinib 25 (μM)

769 (625–980)

2180 (1875–1281)

32.2 (33.4–6.0)a

Lapatinib 25 (μM) + TNF-α and IL-1β

1591 (1165–1865)a

2790 (2045–4151)a

48.0 (36.4–71.6)a

Lapatinib 50 (μM)

1048 (905–1325)

a

1460 (1228–1735)

35.1 (35.9–36.4)a

Lapatinib 50 (μM) + TNF-α and IL-1β

779 (670–845)a

1398 (1268–1531)a

42.2 (38.1–46.8)a

Lapatinib 100 (μM)

1525 (1310–1670)

860 (545–1141)

41.2 (33.8–47.3)a

Lapatinib 100 (μM) + TNF-α and IL-1β

1242 (1030–1585)a

1524 (1291–1841)a

50.0 (47.7–51.6)a

Lapatinib 200 (μM)

1234 (930–1395)

710 (561–861)

38.4 (34.6–40.7)a

Lapatinib 200 (μM) + TNF-α and IL-1β

1194 (730–1475)a

1382 (921–2115)a

51.3 (48.1–5 ± 4)a

a

a

a

a

a

a

a

with the group induced by TNF-α and IL-1β, p < 0.05
MMP; Matrix metalloproteinase, TNF-α; Tumor necrosis factor-α, IL-1β; Interleukin-1β
compared
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Figure 2. The productions of matrix metalloproteinases from synovial fibroblasts IL-1β and TNF-α applications increased the
productions of MMP-1 (A), MMP-3 (B), and MMP-13 (C). Various concentrations of lapatinib decreased the productions of MMP-1
(A), MMP-3 (B), and MMP-13 (C) from RA-FLSs induced by IL-1β and TNF-α MMP; matrix metalloproteinase, IL; interleukin-1β,
TNF-α; tumor necrosis factor.
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Figure 3. The viability of synovial fibroblasts. Various concentrations of lapatinib
inhibited the proliferation of synovial fibroblasts. IL-1β; interleukin-1β, TNF-α;
tumor necrosis factor-α

obtained from a patient with RA was stimulated with
TNF-α and IL-1β cytokines. It was found that the level of
matrix metalloproteinases increased after the stimulation.
It was determined that when lapatinib was added to the
medium (medium or cell culture) together with synovial
fibroblasts TNF-α and IL-1β; MMP-1,-3, and -13 levels
did not increase and their proliferation from synovial
fibroblasts decreased.
The role of the EGF family and the EGFR signal
pathway in angiogenesis regulation and hyperplastic
growth of several tissues, as well as tumor growth, is well
demonstrated [12,17,18]. Because synovial hyperplasia
and pannus formation which invades cartilage and bone
leading to joint destruction is similar to a tumor with its
neovascularization and cellular infiltration, involvement
of EGF and EGFR in RA pathology has been proposed
[13,19,20].
In this study, it has been shown that cell proliferation
is reduced when lapatinib, an EGFR inhibitor, is added to
the synovial fibroblast cell culture. This result suggests that
EGFR inhibition may prevent the proliferation of synovial
fibroblasts, which are key effector cells in the destruction
of the joint cartilage in RA.
Previous studies reported that there is EGFR expression
in synovial tissue, and EGFR expression is increased in
patients with RA compared to that in the healthy control
group [21,22]. In this study, the suppression of MMP
synthesis with lapatinib, an EGFR inhibitor, in the isolated
synovial fibroblast cell culture, confirmed that synovial
fibroblasts are sensitive to EGFR inhibition and synthesis
EGFR.
As known, MMPs have collagenolytic activity. Indeed,
tissue destruction of the extracellular matrix in RA is

mediated by enzymatic cleavage predominantly by MMPs
[23]. MMPs, cause tissue degradation in the synovial
fibroblast microenvironment. Thus, they could make it
easier for the synovium to invade the underlying tissues.
There is a close link between radiological damage and the
level of MMPs in RA [24]. In this study, the blockade of
EGFR with lapatinib inhibited the synthesis of MMPs from
synovial fibroblasts. This suggests that EGFR inhibition
may prevent matrix degradation and joint damage in the
treatment of RA.
MMPs are involved in angiogenesis. They lead to the
loosening of endothelial tight junctions, reorganization
of the actin cytoskeleton, and proteolysis of the basement
membrane and interstitial matrix [25,26]. Moreover, it
has been reported that MMPs stimulate the synthesis of
angiogenic factors, degradation of antiangiogenic factors,
and interactions with the cellular adhesion molecules
expressed on the cell surface [27]. Conversely, when
considering that EGF and EGFR have been demonstrated
to induce the expressions of MMPs [28], our results
predicted that blocking of EGFR may contribute to
inhibition of angiogenesis in RA. In this study, MMP
synthesis was suppressed by adding an EGFR inhibitor
to the cell culture medium. These results indicate that
EGFR inhibition may have a preventive role for pannus
formation, for which angiogenesis is required.
There are some limitations to this study. The most
important limitation is that our study is in vitro. In in vivo
conditions, the effects of EGFR blockade may be different
due to other mechanisms. It would have been better
if lapatinib had also been tested in an animal model. In
addition, the effect of EGFR blockade on inflammatory
cytokine synthesis could also have been better.
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In conclusion, synovial fibroblasts are sensitive to
lapatinib, an EGFR inhibitor, and lapatinib suppresses
MMP release from synovial fibroblasts. The significant
role of MMP in the steps such as matrix degradation and
angiogenesis, which have a major role in the pathogenesis
of RA, suggests that the EGFR pathway and lapatinib may
be promising pathways and agents in RA.
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